Laura Riva

Employment

• Neomorph Associate Director
  2026 - Present
• Scripps Research Institute Principal Investigator
  2020 - 2026
• Sanford Burnham Prebys Medical Discovery Institute Postdoctoral associate
  2017 - 2020
• Center for Infection and Immunity of Lille Postdoctoral associate
  2013 - 2017

Education

• University of Liège PhD
  2009 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (38)

• Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990
  2026 DOI: 10.64898/2026.09.29.755428
  +Save
• Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead
  Viruses 2026 DOI: 10.3390/v18080821
  +Save
• Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead
  2026 DOI: 10.64898/2026.05.15.725542
  +Save
• Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV-2 Papain-like Protease (PLpro) Inhibitors
  ACS Omega 2025 DOI: 10.1021/acsomega.5c04858
  +Save
• Global siRNA screen identifies human host factors critical for SARS-CoV-2 replication and late stages of infection
  PLOS Biology 2025 DOI: 10.1371/journal.pbio.3002738
  +Save
• Open Source Repurposing Reveals Broad-Spectrum Antiviral Activity of Diphenylureas
  Viruses 2025 DOI: 10.3390/v17030385
  +Save
• Synthesis and Structure-Activity Relationship of Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease with Antiviral Potency
  Bioorganic & Medicinal Chemistry Letters 2025 DOI: 10.1016/j.bmcl.2024.130034
  +Save
• Optimization of a micro-scale air–liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2
  Respiratory Research 2025 DOI: 10.1186/s12931-025-03095-y
  +Save
• An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivo
  Cell Reports 2024 DOI: 10.1016/j.celrep.2024.114929
  +Save
• Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead
  Journal of Medicinal Chemistry 2024 DOI: 10.1021/acs.jmedchem.3c01938
  +Save
• The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms
  Pathogens 2023 DOI: 10.3390/pathogens12121408
  +Save
• Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Covalent Warhead
  2023 DOI: 10.1101/2023.10.24.563688
  +Save
• Multistep Synthesis of Analogues of Remdesivir: Incorporating Heterocycles at the C-1′ Position
  Savio Cardoza, Manoj Kumar Shrivash, Laura Riva +3 more
  The Journal of Organic Chemistry 2023 DOI: 10.1021/acs.joc.3c00754
  +Save
• Recognition of HIV-1 capsid by PQBP1 licenses an innate immune sensing of nascent HIV-1 DNA
  Molecular Cell 2022 DOI: 10.1016/j.molcel.2022.06.010
  +Save
• Sec61 Inhibitor Apratoxin S4 Potently Inhibits SARS-CoV-2 and Exhibits Broad-Spectrum Antiviral Activity
  ACS Infectious Diseases 2022 DOI: 10.1021/acsinfecdis.2c00008
  +Save
• Synthetic lethality-based prediction of anti-SARS-CoV-2 targets
  iScience 2022 DOI: 10.1016/j.isci.2022.104311
  +Save
• Genome‐scale metabolic modeling reveals SARS‐CoV‐2‐induced metabolic changes and antiviral targets
  Molecular Systems Biology 2021 DOI: 10.15252/msb.202110260
  +Save
• The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking De Novo Formation of the Membranous Replication Compartment
  Journal of Virology 2021 DOI: 10.1128/jvi.00996-21
  +Save
• Restriction factor compendium for influenza A virus reveals a mechanism for evasion of autophagy
  Nature Microbiology 2021 DOI: 10.1038/s41564-021-00964-2
  +Save
• Drug repurposing screens identify chemical entities for the development of COVID-19 interventions
  Nature Communications 2021 DOI: 10.1038/s41467-021-23328-0
  +Save